The clinical analysis showed that only RA patients in the low tmTNF RSA group responded with a significant decrease of CRP (Figure 5A) and ESR (Figure 5B) during the initial 12 weeks of therapeutic TNF blockade, whereas the high tmTNF RSA group did not. The gene discussed is TNF; the disease is rheumatoid arthritis.